

Supplemental Figure S1. Cohort Construction



Supplemental Figure S2. Cohort Construction Flowchart

Diabetes diagnosis, outpatient visit criterion, and outpatient visit criterion were ascertained on the basis of ICD-9 and ICD-10 codes (see Methods). Patients with only gestational diabetes (ICD-9 648.8x, ICD-10 O024.4xx) were not included. Pharmacy claim criteria was having a fill for \geq 1 glucose-lowering medication other than metformin within a 12-month period



Supplemental Table S1. Granular Classification Scheme for Medications

Medication class	Included agents
	GLUCOSE-LOWERING MEDICATIONS
Biguanides	Metformin
Sulfonylureas (SU)	Glimepiride
5 ()	Glipizide
	Glyburide
Glitazones (TZD)	Pioglitazone
	Rosiglitazone
DPP-4 inhibitors	alogliptin
	linagliptin
	sitagliptin
	saxagliptin
GLP-1 analogs	exenatide
C	liraglutide
	albiglutide
	dulaglutide
	semaglutide
	lixisenatide
SGLT-2 inhibitors	canagliflozin
	empagliflozin
	dapagliflozin
	ertugliflozin
Glinides	nateglinide
	repaglinide
Amylin analogs	pramlintide
α-Glucosidase inhibitors	acarbose
	miglitol
Insulin: Bolus	Human
	regular
	Analog
	aspart
	lispro
	glulisine
	inhaled powder insulin
	aspart
	lispro
Insulin: Basal	Human
	Neutral Protamine Hagedorn (NPH)
	isophane
	Analog
	determir
	glargine
	degludec
	glargine
	LIPID-LOWERING MEDICATIONS

a st	
Statins	atorvastatin
	fluvastatin
	lovastatin
	pitavastatin
	pravastatin
	rosuvastatin
	simvastatin
PCSK-9 Inhibitors	alirocumab
	evolocumab
Fibrates	bezafibrate
	clofibrate
	fenofibrate
	fenofibric Acid
	gemfibrozil
Ezetimibe	ezetimibe
Bile acid sequestrants	cholestyramine
	colesevelam
	colestipol
Nicotinic acid	niacin
Nicotiffic acid	niacinamide
Other	lomitapide
	mMipomersen
Omega-3 fatty acids	omega-3-acid ethyl esters
	omega-3-carboxylic acids
Combination tablets	aspirin/pravastatin sodium
	ezetimibe/atorvastatin
	ezetimibe/simvastatin
	fenofibrate/smvastatin
	niacin/lovastatin
	niacin/simvastatin
	nicotinic acid/laropiprant
	pravastatin sodium/fenofibrate
	sitagliptin phosphate/simvastatin
	CARDIOVASCULAR MEDICATIONS
ACE inhibitors	benazepril
	captopril
	enalapril
	fosinopril
	lisinopril
	moexipril
	perindopril
	quinapril
	ramipril
	trandolapril
	enalaprilat
	onumprinut

Angiotansin recorder	azilsartan
Angiotensin receptor	
blockers (ARBs)	candesartan
	eprosartan irbesartan
	losartan
	olmesartan
	telmisartan
	valsartan
Direct renin inhibitor	aliskiren
Thiazide diuretics	bendroflumethiazide
	benzthiazide
	chlorothiazide
	chlorthalidone
	cyclothiazide
	diazoxide
	hydrochlorothiazide
	hydroflumethiazide
	indapamide
	methyclothiazide
	metolazone
	polythiazide
	quinethazone
	trichlormethiazide
Loop diuretics	bumetanide
200p dimension	ethacrynate Sodium
	ethacrynic Acid
	furosemide
	torsemide
	amiloride
Potassium-sparing diuretics	
	triamterene
Aldosterone antagonist	eplerenone
	spironolactone
Calcium-channel blockers -	amlodipine
dihydropyridines	felodipine
	isradipine
	nicardipine
	nifedipine
	nisoldipine
	clevidipine
	bumetanide
	ethacrynate Sodium
	ethacrynic Acid
	furosemide
	torsemide
Calcium-channel blockers -	diltiazem
nondihydropyridines	verapamil
Beta-blockers -	atenolol
cardioselective	betaxolol
	bisoprolol
	metoprolol tartrate
	metoprolol succinate

Beta-blockers - cardioselective + vasodilatory	nevibolol
Beta-blockers - noncardioselective Beta-blockers - sympathetomimetic activity	nadolol propranolol acebutolol penbutolol pindolol
Alpha and Beta-blockers	timolol carvedilol labetalol esmolol
Alpha-1 blockers	doxazosin prazosin terazosin alfuzosin
Central antihypertensives	clonidine methyldopa guanfacine
Direct vasodilators	hydralazine minoxidil guanethidine tolazoline sodium nitroprusside nitroglycerin
Nonselective alpha-blockers	phentolamine
Dopamine-receptor agonist	fenoldopam

Supplemental Table S2. Qualifying ICD codes for Diabetes Complications Supplemental Table S2 shows the ICD codes used to define diabetes complications (per DCSI definitions), severe hyperglycemic events, and severe hypoglycemic events.

Category	ICD-9 Codes	ICD-10 Codes
Retinopathy	362.01, 362.03, 362.04, 362.05, 362.06, 362.07, 362.53, 362.81, 362.82, 362.83, 362.02, 379.23, 250.5x, 249.5x, 362.1x, 361.x, 369.x	H359, E08.3x, E09.3x, E10.3x, E11.3x, E13.3x, H35.0x, H35.35x, H35.6x, H35.8x, H33.x, H54.x, H43.1x
Nephropathy	593.9, 586, 250.4x, 249.4x, 580.x, 581.x, 582.x, 583.x, 585.x	E08.21, E08.22, E08.29, E09.21, E09.22, E09.29, E10.21, E10.22, E10.29, E11.21, E11.22, E11.29, E13.21, E13.22, E13.29, N19, N00.x, N03.x, N04.x, N05.x, N18.x
Cerebrovascular	431, 436, 435.x, 433.x, 434.x	I67.81, I61.x, I63.x, I65.x, I66.x, G45.x
Cardiovascular	429.2, 412, 427.5, 427.1, 411.x, 413.x, 414.x, 410.x, 427.3x, 427.4x, 428.x, 440.x, 441.x	I24.x, I20.x, I25.x, I70.x, I21.x, I22.x, I23.x, I48.x, I46.x, I47.x, I49.x, I50.x, I71.x
Peripheral vascular disease	442.3, 440.21, 443.81, 443.9, 892.1, 040.0, 444.22, 785.4, 250.7x, 249.7, 707.1x	E08.51, E09.51, E10.51, E11.51, E13.51, E08.59, E09.59, E10.59, E11.59, E13.59, E08.621, E09.621, E10.621, E11.621, E13.621, I72.4, I73.89, I73.9, A48.0, I74.3, I96, E08.52, E09.52, E10.52, E11.52, E13.52, I70.21x, S91.3x, L97.x
Severe hyperglycemic event	250.10, 250.11, 250.12, 250.13, 250.20, 250.21, 250.22, 250.23	E10.10, E10.11, E11.00, E11.01, E11.10, E11.11, E13.00, E13.01, E13.10, E13.11
Severe hypoglycemic events	251.0, 251.1, 251.2, 962.3; and 250.8x, as long as none of the following are also coded during the same encounter: 259.8, 272.7, 686.9, 707.8, 707.9, 709.3, 731.8, 681.x, 682.x, 707.1x, 707.2x, 730.0x, 730.1x, 730.2x	E10.641, E10.649, E11.641, E11.649, E13.641, E13.649, E16.0, E16.1, E16.2, T383X1A, T383X1D, T383X1S, T383X2A, T383X2D, T383X2S, T383X3A, T383X3D, T383X3S, T383X4A, T383X4D, T383X4S, T383X5A, T383X5D, T383X5S

Supplemental Table S3. Properties of Commercial Cohort

Average annual changes represent relative and absolute changes in either proportions or means. Changes are calculated for the period from 2006 to 2018, except for SGLT-2 inhibitors, for which changes are calculated from 2013 to 2018. P-values represent trends from 2006 to 2018, and p-values <0.05 are bolded. Green text indicates an increase, while red text indicates a decrease. All medication data is based on numbers of filled prescriptions. HbA_{1c} cutoffs of 7.0% and 8.0% are equivalent to 53 mmol/mol and 64 mmol/mol, respectively.

Variable	p- value	Avg. Annual Relative Change	Avg. Annual Absolute Change	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Cohort size				393046	436460	451113	460069	456654	459222	452232	445045	400824	412659	432683	440304	386845
Glucose- lowering medications																
Basal Insulin- Analog	0.005	4.3%	0.4%	10.5%	11.8%	13.6%	14.3%	14.7%	15.1%	15.7%	16.3%	16.4%	16.0%	16.0%	15.2%	16.3%
Basal Insulin- Human	<0.001	-5.4%	-0.2%	4.0%	3.6%	3.3%	3.0%	2.7%	2.4%	2.2%	2.0%	1.8%	1.6%	1.5%	1.3%	1.2%
Biguanides	<0.001	5.6%	1.9%	34.5%	41.9%	48.6%	49.8%	50.6%	50.7%	50.7%	51.3%	53.9%	54.8%	56.6%	58.6%	59.8%
Bolus Insulin- Analog	0.92	0.9%	0.1%	10.6%	11.2%	12.4%	12.7%	12.7%	12.7%	12.8%	13.0%	12.6%	11.9%	11.6%	11.4%	11.9%
Bolus Insulin- Human	<0.001	-4.8%	-0.2%	3.4%	3.1%	2.8%	2.5%	2.3%	2.1%	1.9%	1.7%	1.5%	1.5%	1.4%	1.2%	1.3%
DPP-4 inhibitors	0.047	184.8%	0.9%	0.5%	5.5%	9.2%	10.6%	11.8%	13.7%	15.3%	14.9%	14.2%	13.2%	12.8%	12.5%	12.5%
Glitazones	0.002	-5.7%	-1.2%	21.8%	22.8%	19.8%	18.4%	16.5%	13.0%	8.0%	5.9%	5.4%	5.2%	5.2%	5.2%	5.6%
GLP-1 agonists	<0.001	17.6%	0.7%	4.2%	5.3%	5.5%	4.6%	5.0%	5.7%	6.4%	6.7%	6.7%	7.7%	9.2%	11.1%	13.8%
SGLT2 inhibitors	0.002	177.8%	2.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.2%	5.1%	9.0%	10.6%	12.1%	13.8%
Sulfonylureas	0.10	0.2%	0.0%	22.1%	25.0%	27.3%	26.7%	26.0%	25.2%	24.4%	24.0%	23.2%	22.6%	22.5%	22.4%	22.6%
Classes of glucose- lowering medications																
0 Unique Classes	0.01	-3.0%	-1.2%	38.4%	33.7%	27.7%	27.5%	27.4%	28.0%	28.7%	28.8%	27.8%	27.4%	25.8%	24.3%	23.3%
1 Unique Class	0.001	0.7%	0.2%	26.9%	25.5%	27.4%	27.8%	28.3%	28.6%	29.1%	29.3%	29.7%	29.6%	30.3%	31.1%	29.4%

2 Unique																
Classes	0.16	0.4%	0.1%	23.1%	24.4%	26.8%	26.5%	26.0%	25.4%	25.0%	24.7%	24.4%	23.9%	24.1%	24.0%	24.3%
3 Unique																
Classes	0.04	4.7%	0.4%	8.8%	11.4%	12.5%	12.6%	12.5%	12.3%	11.9%	12.0%	12.1%	12.3%	12.7%	13.1%	14.2%
4 Unique	0.003	14.00/	0.20/	2.2%	3.8%	4.4%	4.4%	4.5%	4.5%	4.2%	4.1%	4.6%	5.1%	5 20/	5 (0/	6.50/
Classes >= 5 Unique	0.003	14.9%	0.3%	2.2%	3.8%	4.4%	4.4%	4.5%	4.5%	4.2%	4.1%	4.0%	5.1%	5.3%	5.6%	6.5%
Classes	0.01	22.9%	0.1%	0.6%	1.2%	1.3%	1.2%	1.2%	1.2%	1.2%	1.2%	1.5%	1.7%	1.9%	2.0%	2.4%
Mean (SD)	0.01	22.970	0.170	1.11	1.270	1.42	1.4	1.42	1.270	1.270	1.270	1.41	1.43	1.47	1.51	1.59
Classes	0.01	3.3%	0.037	(1.12)	(1.23)	(1.22)	3(1.22)	(1.22)	(1.22)	(1.21)	(1.21)	(1.23)	(1.26)	(1.26)	(1.26)	(1.30)
Classes of						· · · · ·										
cardio-																
vascular																
medications																
0 Unique Classes	0.003	-3.2%	-1.7%	52.6%	45.3%	37.0%	35.6%	34.9%	34.5%	34.8%	34.6%	34.9%	35.0%	34.1%	33.0%	30.8%
1 Unique	0.000	5.270	1.770	52.070	45.570	57.070	55.070	54.970	54.570	54.070	54.070	54.970	55.070	54.170	55.070	50.070
Class	<0.001	2.7%	0.5%	18.6%	19.4%	21.1%	21.2%	21.5%	21.9%	22.0%	22.3%	23.3%	23.5%	24.0%	24.6%	25.1%
2 Unique																
Classes	<0.001	2.7%	0.2%	8.4%	8.8%	9.8%	10.0%	10.2%	10.3%	10.4%	10.5%	10.5%	10.5%	10.7%	11.0%	11.4%
3 Unique	0.17	2.20/	0.20/	10.20/	12.00/	12.00/	14.20/	14.20/	14 407	14 407	14 407	14 10/	12.00/	14.00/	14.20/	14 40/
Classes 4 Unique	0.17	3.2%	0.3%	10.2%	12.0%	13.9%	14.2%	14.3%	14.4%	14.4%	14.4%	14.1%	13.9%	14.0%	14.2%	14.4%
Classes	0.58	5.4%	0.3%	6.0%	8.1%	9.9%	10.2%	10.2%	10.1%	10.0%	10.0%	9.6%	9.6%	9.6%	9.8%	10.2%
>= 5 Unique												,	,	,	,	
Classes	0.75	6.8%	0.3%	4.3%	6.5%	8.4%	8.8%	8.9%	8.7%	8.4%	8.3%	7.6%	7.5%	7.5%	7.5%	8.1%
Mean (SD)				1.13	1.41	1.69	1.74	1.75	1.75	1.73	1.72	1.67	1.66	1.68	1.70	1.77
Classes	0.31	4.4%	0.049	(1.56)	(1.72)	(1.81)	(1.83)	(1.83)	(1.81)	(1.80)	(1.79)	(1.75)	(1.74)	(1.74)	(1.73)	(1.75)
Classes of																
lipid- lowering																
medications																
0 Unique																
Classes	0.01	-2.7%	-1.7%	63.0%	55.5%	48.5%	45.6%	44.5%	44.2%	44.8%	44.9%	44.9%	45.6%	44.7%	43.2%	40.7%
1 Unique	0.001		• • • • •				• • • • • •		10 10/			15 10 (16.004	10.00/	T O 00/	
Class	<0.001	7.7%	2.0%	26.3%	30.2%	36.1%	39.9%	41.5%	43.1%	44.2%	45.2%	46.4%	46.8%	48.2%	50.0%	52.5%
2 Unique Classes	0.003	-2.6%	-0.2%	9.3%	12.0%	12.7%	11.9%	11.5%	10.6%	9.4%	8.5%	7.6%	6.8%	6.4%	6.0%	6.2%
3 Unique	0.005	2.070	0.270	7.570	12.070	12.//0	11.770	11.270	10.070	⊅ • ⊤ ∕∪	0.570	7.070	0.070	0.770	0.070	0.270
Classes	0.003	-3.9%	0.0%	1.3%	2.0%	2.4%	2.2%	2.2%	1.8%	1.5%	1.2%	1.0%	0.8%	0.7%	0.6%	0.6%
4 Unique																
Classes	0.01	-3.8%	0.0%	0.1%	0.3%	0.4%	0.3%	0.3%	0.3%	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%
>= 5 Unique	0.00	0.00/	0.00/	0.00/	0.00/	0.00/	0.00/	0.00/	0.00/	0.00/	0.00/	0.00/	0.00/	0.00/	0.00/	0.00/
Classes	0.03	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Mean (SD)				0.49	0.61	0.70	0.72	0.72	0.71	0.68	0.66	0.65	0.63	0.63	0.64	0.67
Classes	0.81	2.8%	0.014	(0.73)	(0.80)	(0.81)	(0.79)	(0.78)	(0.75)	(0.72)	(0.70)	(0.67)	(0.65)	(0.64)	(0.63)	(0.63)
Total # of																
(any)																
medication																
classes																
0 Medication																
Classes	0.09	-3.3%	-0.3%	8.7%	13.0%	7.1%	6.2%	5.6%	5.1%	5.2%	5.4%	6.0%	7.2%	6.5%	5.6%	5.0%
1 Unique																
Class	0.06	-4.5%	-0.3%	7.6%	4.3%	3.7%	3.6%	3.7%	3.7%	3.8%	3.9%	3.9%	3.7%	3.7%	3.5%	3.1%
2 Unique	0.04		a 1 0 (10.10/	c 10/											1.50/
Classes	0.01	-4.2%	-0.4%	10.1%	6.4%	5.7%	5.6%	5.6%	5.6%	5.7%	5.7%	5.8%	5.5%	5.4%	5.2%	4.6%
3 Unique	0.02	2.20/	0 40/	11.00/	0.00/	7 40/	7.00/	7 10/	7.00/	7 20/	7 20/	7 40/	7.00/	7 10/	7.00/	C 40/
Classes	0.02	-3.3%	-0.4%	11.0%	8.0%	7.4%	7.2%	7.1%	7.2%	7.3%	7.3%	7.4%	7.2%	7.1%	7.0%	6.4%
4 Unique	0.02	-2.1%	-0.2%	11.2%	8.9%	8.8%	8.5%	8.6%	8.7%	8.7%	8.7%	8.8%	8.5%	8.5%	8.4%	8.1%
Classes 5 Unique	0.02	-2.1%	-0.270	11.270	0.9%	0.0%	0.3%	0.0%	0./%	0./%	0./%	0.0%	0.3%	0.3%	0.4%	0.170
Classes	0.92	-0.9%	-0.1%	10.5%	9.3%	9.5%	9.4%	9.3%	9.4%	9.5%	9.6%	9.6%	9.5%	9.6%	9.5%	9.3%
6 Unique	0.72	-0.970	-0.170	10.570	7.570	7.570	J. T /0	7.570	7.770	7.570	7.070	7.070	7.570	7.070	7.570	7.570
Classes	0.002	0.5%	0.0%	9.3%	9.1%	9.5%	9.6%	9.6%	9.6%	9.8%	9.8%	9.7%	9.7%	9.8%	9.8%	9.8%
7 Unique	00002	0.070	01070	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,	,,	,,,,,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,,,,,	,,,,,	2.17.0	,,,,,,	,,	,,,,,,,
Classes	0.001	1.9%	0.2%	7.9%	8.4%	9.2%	9.2%	9.2%	9.4%	9.4%	9.3%	9.4%	9.4%	9.5%	9.7%	9.8%
8 Unique																
Classes	0.01	3.4%	0.2%	6.3%	7.4%	8.2%	8.5%	8.5%	8.6%	8.6%	8.6%	8.5%	8.4%	8.6%	8.8%	9.1%
9 Unique																
Classes	0.02	4.8%	0.2%	4.9%	6.3%	7.2%	7.4%	7.5%	7.5%	7.5%	7.4%	7.3%	7.3%	7.4%	7.5%	7.9%
>= 10																
Unique		0.00/			10.10/		• • • • • •	a a i a i		• • • • • •				• • • • • •	• • • • • •	• • • • • • •
Classes	0.13	8.8%	1.1%	12.6%	19.1%	23.7%	24.8%	25.4%	25.3%	24.6%	24.3%	23.6%	23.7%	24.1%	24.9%	26.9%
Mean (SD)	0.07	3.0%	0.16	5.15	5.88	6.67	6.84	6.92	6.94	6.87	6.81	6.72	6.68	6.77	6.91	7.18
Any Class	0.07	3.0%	0.16	(3.68)	(4.22)	(4.20)	(4.20)	(4.21)	(4.18)	(4.14)	(4.11)	(4.12)	(4.15)	(4.15)	(4.12)	(4.14)
Actively																
managed DCSI																
categories-																
Count																
No DCSI																
Complication	0.26	0.1%	0.0%	66.7%	67.5%	68.0%	68.1%	68.3%	68.7%	68.9%	68.6%	69.4%	68.0%	68.3%	68.3%	67.2%
1 DCSI																
Complication	0.17	-0.2%	0.0%	22.6%	22.1%	21.9%	21.7%	21.6%	21.3%	21.2%	21.4%	21.0%	21.6%	21.6%	21.7%	22.1%
2 DCSI																
Complication	0.66	0.2%	0.0%	7.1%	6.9%	6.7%	6.8%	6.7%	6.7%	6.6%	6.7%	6.5%	7.0%	6.9%	6.9%	7.3%
3 DCSI																
Complication	0.23	-0.1%	0.0%	2.5%	2.3%	2.3%	2.3%	2.3%	2.2%	2.2%	2.2%	2.1%	2.3%	2.2%	2.2%	2.4%

4 DCSI																
Complication	0.02	-0.8%	0.0%	0.9%	0.8%	0.8%	0.8%	0.8%	0.8%	0.8%	0.8%	0.7%	0.8%	0.7%	0.7%	0.8%
>= 5 DCSI																
Complication	<0.001	-2.3%	0.0%	0.4%	0.4%	0.3%	0.4%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%
Mean (SD)				0.50	0.48	0.47	0.47	0.47	0.46	0.46	0.46	0.45	0.47	0.46	0.46	0.49
DCSI	0.14	-0.2%	-0.001	(0.86)	(0.85)	(0.83)	(0.84)	(0.83)	(0.83)	(0.82)	(0.82)	(0.81)	(0.83)	(0.82)	(0.81)	(0.84)
Actively																
managed DCSI types																
and other																
complication																
S																
Cardiovascula				15.34	14.88	14.54	14.44	14.15	13.78	13.45	13.25	12.46	12.67	13.26	13.39	
r Disease	0.01	-0.7%	-0.1%	%	%	%	%	%	%	%	%	%	%	%	%	13.96%
Cerebro	0.04	0.504	0.00/	0.5 (0)	0.500/	0.5.00	a (00)	0 (10)	0.0000	0.500/	0.5.00	0.050/	a a a a a	0.000/	0.010/	0.410/
Disease	0.04	-0.5%	0.0%	2.56%	2.53%	2.56%	2.60%	2.61%	2.62%	2.59%	2.56%	2.35%	2.38%	2.23%	2.31%	2.41%
Nephropathy	<0.001	3.3%	0.2%	6.27%	6.33%	6.40%	6.81%	7.03%	7.10%	7.06%	7.29%	7.18%	7.73%	8.03%	8.34%	8.98%
Neuropathy	0.01	0.00/	0.10/	11.23	10.96	10.83	10.83	10.81	10.75	10.93	11.38	11.33	12.25	12.16	12.21	10 500/
Peripheral	0.01	0.9%	0.1%	%	%	%	%	%	%	%	%	%	%	%	%	12.58%
Vascular																
Disease	0.72	1.7%	0.1%	4.39%	4.20%	4.04%	4.06%	4.02%	3.93%	3.86%	3.82%	3.67%	3.87%	4.39%	4.76%	5.35%
Retinopathy	< 0.001	-4.1%	-0.2%	5.88%	5.51%	5.13%	4.94%	4.62%	4.39%	4.27%	4.28%	4.09%	4.17%	3.93%	2.70%	2.72%
Severe	-0.001	1.170	0.270	5.0070	5.5170	5.1570	1.9170	1.0270	1.5570	1.2770	1.2070	1.0970	1.1770	5.9570	2.7070	2.7270
Hyperglycemi																
a	0.10	-2.1%	0.0%	1.12%	0.99%	0.96%	0.85%	0.83%	0.81%	0.77%	0.76%	0.77%	0.82%	0.85%	0.93%	0.82%
Severe																
Hypoglycemi	0.11	2 10/	0.10/	2 0 0 0 /	2 700/	2 750/	2 700/	2 710/	2 720/	2 700/	2 750/	2 000/	2 220/	1 500/	1 570/	1 720/
a	0.11	-3.1%	-0.1%	2.88%	2.78%	2.75%	2.70%	2.71%	2.73%	2.70%	2.75%	2.88%	3.32%	1.50%	1.57%	1.72%
Actively Managed																
CCS Health																
Conditions																
1 CCS												10.96	11.01	11.33	10.48	
Category	0.01	1.3%	0.1%	9.01%	9.81%	9.60%	9.61%	9.66%	9.55%	9.57%	9.71%	%	%	%	%	10.55%
2 CCS	0.001	2 20 (0.10/	1.6604	4.400/	4.1.20/	2 0 60 (2 5 00/		0.600/	a 400/	0 (10 (0.010/	a a a a a a a a a a	a a a a (2.269/
Categories 3 CCS	<0.001	-2.3%	-0.1%	4.66%	4.40%	4.13%	3.86%	3.79%	3.76%	3.62%	3.49%	3.64%	3.31%	3.30%	3.29%	3.26%
Categories	<0.001	-2.2%	-0.2%	6.98%	6.67%	6.43%	6.20%	6.02%	5.92%	5.74%	5.54%	5.62%	5.09%	5.26%	5.13%	4.96%
4 CCS	-0.001	2.270	0.270	0.9070	0.0770	0.4370	0.2070	0.0270	5.5270	5.7470	5.5470	5.0270	5.0770	5.2070	5.1570	4.9070
Categories	<0.001	-1.8%	-0.2%	9.03%	8.79%	8.62%	8.48%	8.45%	8.46%	8.12%	8.05%	8.12%	7.37%	7.27%	7.19%	6.92%
5 CCS																
Categories	0.003	-0.5%	0.0%	8.61%	8.45%	8.37%	8.19%	8.35%	8.31%	8.21%	8.22%	8.31%	7.96%	8.10%	8.14%	8.02%
6 CCS	.0.001	0.00/	0.10/	0.000/	0.0.10/	0.150/	0.000/	0.150/	0.1.50/	0.120/	= 0 (0 (= 000/	10/			7 5 6 6 6
Categories	<0.001	-0.8%	-0.1%	8.39%	8.24%	8.17%	8.22%	8.15%	8.15%	8.12%	7.96%	7.92%	7.71%	7.70%	7.67%	7.50%

7 CCS																
Categories	0.01	-0.4%	0.0%	7.51%	7.50%	7.57%	7.52%	7.50%	7.50%	7.51%	7.53%	7.43%	7.38%	7.35%	7.42%	7.16%
8 CCS																
Categories	0.02	-0.1%	0.0%	6.76%	6.72%	6.76%	6.71%	6.71%	6.81%	6.80%	6.71%	6.69%	6.72%	6.69%	6.69%	6.67%
9 CCS																
Categories	0.004	0.4%	0.0%	5.76%	5.80%	5.85%	5.91%	5.90%	5.97%	5.93%	5.92%	5.87%	5.94%	5.93%	6.02%	6.03%
>=10 CCS				33.28	33.61	34.50	35.29	35.48	35.57	36.37	36.87	35.45	37.50	37.07	37.97	
Categories	0.001	1.3%	0.4%	%	%	%	%	%	%	%	%	%	%	%	%	38.91%
Mean (SD)						- 						0.07		-		
CCS	0.003	0.70/	0.000	8.59	8.63	8.77	8.89	8.91	8.94	9.04	9.09	8.86	9.17	9.07	9.23	9.37
Categories	0.002	0.7%	0.060	(6.90)	(6.96)	(7.03)	(7.10)	(7.09)	(7.09)	(7.12)	(7.13)	(7.08)	(7.27)	(7.19)	(7.22)	(7.33)
Health Care																
Utilization																
Mean (SD)																
Ambulatory				6.86	6.79	6.73	6.75	6.62	6.51	6.43	6.48	6.23	6.17	6.15	6.16	6.19
visits	0.001	-0.8%	-0.052	(6.15)	(6.20)	(6.17)	(6.23)	(6.11)	(6.06)	(6.01)	(6.18)	(6.02)	(5.97)	(5.97)	(5.95)	(6.04)
Mean (SD)																
Emergency																
Department	0.001	0.00/	0.000	0.26	0.26	0.26	0.26	0.26	0.27	0.27	0.27	0.28	0.29	0.30	0.3	0.29
Visits	0.001	0.9%	0.002	(0.87)	(0.96)	(0.88)	(0.91)	(1.16)	(1.05)	(0.90)	(0.95)	(1.0)	(1.12)	(1.14)	(0.93)	(0.93)
Mean (SD) Hospitalizatio				0.19	0.18	0.17	0.17	0.16	0.15	0.14	0.14	0.13	0.13	0.12	0.12	0.11
ns	<0.001	-3.2%	-0.006	(0.60)	(0.18)	(0.17)	(0.57)	(0.55)	(0.54)	(0.52)	(0.14)	(0.48)	(0.47)	(0.12)	(0.46)	(0.45)
HbA _{1c}	~0.001	-3.270	-0.000	(0.00)	(0.50)	(0.57)	(0.57)	(0.55)	(0.54)	(0.52)	(0.50)	(0.40)	(0.47)	(0.77)	(0.40)	(0.+3)
								- 10	- 10		- 10				- 10	- 10
Mean (SD)	0.00	0.070/	0.540/	7.47	7.36	7.37	7.47	7.48	7.48	7.45	7.49	7.57	7.59	7.56	7.48	7.40
HbA_{1c}	0.09	-0.07%	-0.54%	(1.72)	(1.65)	(1.66)	(1.69)	(1.68)	(1.75)	(1.72)	(1.73)	(1.76)	(1.75)	(1.73)	(1.72)	(1.71)
$HbA_{1c} < 7.0\%$	0.13	0.25%	0.12%	48.9%	53.3%	53.0%	50.2%	49.2%	51.2%	51.2%	50.0%	47.3%	46.8%	47.1%	49.2%	50.5%
$HbA_{1c} \ge 8.0\%$	0.04	-0.05%	-0.02%	28.0%	25.1%	26.0%	27.4%	27.8%	27.4%	27.3%	28.8%	30.4%	30.5%	30.1%	29.0%	27.8%

Supplemental Table S4. Properties of Medicare Advantage Cohort

Average annual changes represent relative and absolute changes in either proportions or means. Changes are calculated for the period from 2006 to 2018, except for SGLT-2 inhibitors, for which changes are calculated from 2013 to 2018. P-values represent trends from 2006 to 2018, and p-values <0.05 are bolded. Green text indicates an increase, while red text indicates a decrease. All medication data is based on numbers of filled prescriptions. HbA_{1c} cutoffs of 7.0% and 8.0% are equivalent to 53 mmol/mol and 64 mmol/mol, respectively.

Variable	p- value	Avg. Annual Relative Change	Avg. Annual Absolute Change	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Cohort size				65583	97816	133230	184439	242461	291044	363848	410773	431868	465814	656531	819285	797151
Glucose- lowering medications, individual classes																
Basal Insulin- Analog	<0.001	7.0%	0.7%	10.4%	12.0%	13.9%	15.3%	16.0%	16.9%	17.5%	18.3%	19.1%	18.7%	19.7%	19.4%	19.8%
Basal Insulin- Human	0.049	-6.3%	-0.8%	11.9%	9.9%	8.5%	7.0%	5.9%	5.1%	4.3%	3.7%	3.3%	3.0%	2.9%	2.4%	2.2%
Biguanides	<0.001	2.5%	1.0%	38.5%	38.7%	39.5%	42.1%	43.8%	44.6%	45.0%	45.8%	47.2%	47.5%	49.2%	50.4%	51.0%
Bolus Insulin- Analog	0.44	6.2%	0.4%	6.6%	7.5%	9.0%	10.1%	10.8%	11.4%	11.8%	12.2%	12.7%	12.4%	12.4%	12.0%	11.9%
Bolus Insulin- Human	0.46	-6.2%	-0.8%	12.3%	11.0%	9.3%	7.8%	6.6%	5.6%	4.6%	3.9%	3.4%	3.0%	3.0%	2.6%	2.3%
DPP-4 inhibitors	0.557	492.7%	0.9%	0.2%	2.9%	4.3%	5.1%	6.6%	8.6%	10.8%	11.3%	12.1%	11.5%	12.0%	12.2%	12.4%
Glitazones	0.034	-5.8%	-1.3%	21.7%	19.6%	14.9%	13.1%	11.8%	9.0%	5.6%	4.2%	4.1%	4.2%	4.7%	4.9%	5.3%
GLP-1 agonists	<0.001	32.6%	0.4%	1.2%	1.1%	1.1%	1.2%	1.3%	1.5%	1.9%	2.2%	2.5%	2.7%	3.6%	4.7%	6.0%
SGLT2 inhibitors	0.002	450.0%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	0.9%	2.0%	3.0%	3.9%	4.5%
Sulfonylureas	<0.001	-3.2%	-1.5%	45.9%	40.9%	38.1%	36.7%	35.2%	33.8%	32.2%	30.6%	28.9%	27.2%	27.4%	26.6%	26.6%
Glucose- lowering medications, total classes																
0 Unique Classes	0.50	2.1%	0.4%	20.4%	25.4%	27.1%	26.9%	27.0%	27.0%	27.7%	28.2%	27.7%	28.7%	26.5%	26.3%	26.0%
1 Unique Class	0.02	-0.1%	0.0%	32.3%	29.2%	29.2%	29.5%	30.0%	30.8%	31.1%	31.2%	31.4%	31.7%	32.3%	32.5%	31.9%

2 Unique																
Classes	<0.001	-1.7%	-0.5%	30.7%	28.1%	27.3%	27.4%	26.7%	26.5%	26.0%	25.6%	25.4%	24.2%	24.6%	24.0%	24.1%
3 Unique																
Classes	0.11	-0.2%	0.0%	12.6%	12.4%	11.8%	11.9%	11.9%	11.4%	11.1%	11.0%	11.3%	10.9%	11.6%	11.7%	12.2%
4 Unique	0.15	2.10/	0.10/	2.20/	2.00/	2 (0)	2 50/	2.50/	2 40/	2.00/	2.00/	2 40/	2 50/	2.00/	4.00/	4.50/
Classes	0.15	3.1%	0.1%	3.2%	3.9%	3.6%	3.5%	3.5%	3.4%	3.2%	3.2%	3.4%	3.5%	3.9%	4.2%	4.5%
>= 5 Unique Classes	0.11	5.3%	0.0%	0.9%	1.1%	1.0%	0.9%	0.9%	0.9%	0.8%	0.8%	0.9%	1.0%	1.2%	1.3%	1.5%
Mean (SD)	0.11	5.570	0.070	1.49	1.170	1.39	1.38	1.38	1.36	1.34	1.32	1.34	1.32	1.270	1.370	1.370
Classes	0.24	-0.4%	-0.005	(1.10)	(1.18)	(1.17)	(1.16)	(1.16)	(1.15)	(1.14)	(1.14)	(1.15)	(1.17)	(1.18)	(1.19)	(1.21)
Cardiovascul	0.21	0.170	0.005	(1.10)	(1.10)	(1.17)	(1.10)	(1.10)	(1.13)	(1.1.1)	(1.1.1)	(1.15)	(1.17)	(1.10)	(1.17)	(1.21)
ar																
medications																
0 Unique																
Classes	0.001	-1.8%	-0.3%	17.4%	19.1%	19.3%	18.4%	17.3%	16.1%	16.0%	15.4%	15.3%	15.7%	14.9%	14.7%	13.3%
1 Unique	0.000	0.00/	0.10/	15.00/	15 10/	15 00/	15 50/	1 5 50 /	16 201	16 70/	17 10/	17 (0)	10.00/	17.00/	17 00/	17 (0)
Class	0.002	0.9%	0.1%	15.9%	15.1%	15.2%	15.5%	15.7%	16.3%	16.7%	17.1%	17.6%	18.0%	17.8%	17.9%	17.6%
2 Unique Classes	<0.001	1.6%	0.2%	12.6%	12.4%	12.6%	12.8%	13.2%	13.7%	14.2%	14.4%	14.8%	15.0%	15.0%	15.1%	15.2%
3 Unique	\0.001	1.070	0.270	12.070	12.470	12.070	12.070	13.270	13.770	14.270	14.470	14.070	13.070	13.070	13.170	13.270
Classes	0.25	-0.1%	0.0%	17.5%	16.5%	16.5%	16.5%	16.8%	17.1%	17.1%	17.2%	17.1%	17.0%	17.1%	17.1%	17.2%
4 Unique														- ,		
Classes	0.06	-0.4%	-0.1%	17.7%	16.9%	16.4%	16.7%	16.6%	16.8%	16.6%	16.6%	16.5%	16.2%	16.5%	16.4%	16.7%
>= 5 Unique																
Classes	0.15	0.4%	0.1%	19.1%	20.0%	19.9%	20.2%	20.4%	20.0%	19.4%	19.4%	18.7%	18.1%	18.7%	18.9%	20.0%
Mean (SD)				2.71	2.70	2.68	2.72	2.75	2.75	2.72	2.73	2.70	2.65	2.70	2.71	2.79
Classes	0.70	0.2%	0.006	(1.96)	(2.03)	(2.03)	(2.03)	(2.01)	(1.98)	(1.97)	(1.95)	(1.93)	(1.92)	(1.92)	(1.92)	(1.93)
Lipid- lowering medications																
0 Unique																
Classes	<0.001	-3.3%	-1.6%	47.3%	44.5%	42.3%	39.1%	36.5%	34.7%	34.1%	33.2%	32.5%	32.2%	30.9%	29.5%	26.8%
1 Unique																
Class	<0.001	4.1%	1.7%	42.2%	43.1%	45.5%	49.7%	52.1%	54.2%	55.7%	56.8%	58.1%	59.2%	60.9%	62.3%	64.8%
2 Unique																
Classes	0.384	-1.4%	-0.1%	9.4%	10.9%	10.6%	9.9%	10.0%	9.7%	9.1%	8.9%	8.5%	7.8%	7.5%	7.5%	7.6%
3 Unique	0.003	0.00/	0.00/	1 10/	1 407	1 50/	1.20/	1 20/	1.00/	1 10/	1.00/	0.00/	0.00/	0.70/	0.70/	0.70/
Classes	0.003	-2.3%	0.0%	1.1%	1.4%	1.5%	1.3%	1.3%	1.2%	1.1%	1.0%	0.9%	0.8%	0.7%	0.7%	0.7%
4 Unique Classes	0.03	0.0%	0.0%	0.1%	> 0.12%	0.1%	0.1%	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
>= 5 Unique	0.03	0.070	0.070	0.170	0.12/0	0.170	0.170	0.270	0.1/0	0.170	0.170	0.170	0.170	0.170	0.170	0.170
Classes	0.77	0.0%	0.0%	0.0%	NA	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Mean (SD)				0.64	0.70	0.72	0.74	0.77	0.78	0.78	0.78	0.78	0.77	0.78	0.80	0.83
Classes	0.002	2.3%	0.015	(0.70)	(0.73)	(0.72)	(0.70)	(0.69)	(0.68)	(0.66)	(0.65)	(0.64)	(0.62)	(0.61)	(0.60)	(0.59)
Total # of																
(any)																
· •/							-							•		

medication classes																
0 Medication Classes	0.004	-4.3%	-0.2%	4.1%	5.5%	5.9%	5.1%	4.1%	2.2%	2.1%	2.0%	2.1%	2.2%	2.1%	1.8%	1.8%
1 Unique Class	0.01	-2.9%	-0.1%	2.1%	1.9%	2.0%	1.8%	1.8%	1.8%	1.9%	1.8%	1.8%	1.9%	1.7%	1.7%	1.3%
2 Unique Classes	0.003	-2.8%	-0.1%	3.1%	2.9%	2.8%	2.8%	2.7%	2.7%	2.7%	2.6%	2.6%	2.8%	2.5%	2.5%	2.0%
3 Unique Classes	0.03	-2.2%	-0.1%	4.4%	3.9%	3.9%	3.8%	3.6%	3.7%	3.8%	3.7%	3.8%	3.9%	3.6%	3.5%	3.1%
4 Unique Classes	0.13	-1.9%	-0.1%	5.7%	5.1%	5.3%	5.0%	4.9%	5.0%	5.2%	5.1%	5.1%	5.3%	5.0%	4.8%	4.3%
5 Unique Classes	0.49	-1.6%	-0.1%	7.3%	6.3%	6.4%	6.4%	6.2%	6.3%	6.5%	6.4%	6.5%	6.7%	6.4%	6.2%	5.8%
6 Unique Classes	0.532	-1.2%	-0.1%	8.4%	7.6%	7.6%	7.5%	7.4%	7.6%	7.7%	7.7%	7.7%	7.9%	7.7%	7.4%	7.1%
7 Unique Classes	0.820	-0.7%	-0.1%	9.1%	8.4%	8.3%	8.3%	8.3%	8.3%	8.6%	8.7%	8.6%	8.8%	8.6%	8.4%	8.2%
8 Unique Classes	0.28	-0.3%	0.0%	9.3%	8.6%	8.7%	8.7%	8.7%	8.8%	9.0%	9.0%	9.0%	9.2%	9.0%	8.9%	8.9%
9 Unique Classes	0.09	0.1%	0.0%	9.0%	8.6%	8.4%	8.6%	8.7%	9.0%	8.9%	9.0%	8.9%	8.9%	9.0%	8.8%	9.0%
>= 10 Unique																
Classes Mean (SD)	0.004	2.2%	0.8%	37.6% 8.31	41.3%	40.8% 8.55	42.1% 8.71	43.6% 8.91	44.6% 9.12	43.6% 9.01	44.0% 9.05	43.8% 9.04	42.5% 8.89	44.4% 9.10	46.0% 9.28	48.5% 9.55
Any Class	0.004	1.1%	0.10	(4.38)	(4.67)	(4.71)	(4.66)	(4.62)	(4.52)	(4.45)	(4.43)	(4.46)	(4.40)	(4.45)	(4.49)	(4.47)
Actively managed DCSI categories- Count																
No DCSI Complication	0.001	-1.1%	-0.5%	40.9%	40.6%	40.8%	40.0%	39.8%	40.0%	39.7%	39.3%	40.0%	39.0%	38.3%	36.2%	34.9%
1 DCSI Complication	0.13	-0.2%	-0.1%	29.5%	28.9%	28.8%	29.1%	29.5%	29.5%	29.5%	29.4%	28.7%	28.3%	28.8%	29.0%	28.8%
2 DCSI Complication	0.001	1.4%	0.2%	16.5%	16.8%	16.8%	17.1%	17.2%	17.1%	17.2%	17.4%	17.2%	17.7%	18.2%	18.9%	19.5%
3 DCSI Complication	<0.001	2.2%	0.2%	8.2%	8.4%	8.4%	8.4%	8.5%	8.4%	8.4%	8.6%	8.7%	9.2%	9.2%	9.9%	10.5%
4 DCSI Complication	0.005	2.7%	0.1%	3.4%	3.6%	3.6%	3.7%	3.5%	3.5%	3.6%	3.7%	3.8%	4.0%	3.9%	4.3%	4.6%
>= 5 DCSI Complication	0.26	1.3%	0.0%	1.5%	1.7%	1.7%	1.7%	1.6%	1.5%	1.6%	1.6%	1.7%	1.8%	1.6%	1.7%	1.8%
Mean (SD) DCSI	0.002	1.3%	0.014	1.09 (1.22)	1.11 (1.24)	1.11 (1.24)	1.13 (1.25)	1.12 (1.23)	1.11 (1.22)	1.12 (1.23)	1.13 (1.23)	1.13 (1.25)	1.17 (1.27)	1.17 (1.24)	1.22 (1.26)	1.27 (1.27)

Actively managed DCSI types and other																
complicatio																
ns Cardiovascula																
r Disease	0.60	0.4%	0.1%	38.97%	39.26%	38.78%	38.97%	38.75%	38.37%	38.36%	37.78%	36.49%	36.80%	37.87%	39.56%	40.80%
Cerebro	0.00	0.170	0.170	50.9770	37.2070	20.7070	50.5770	50.7570	50.5770	50.5070	51.1070	50.1970	20.0070	57.0770	57.5070	10.0070
Disease	0.01	-0.3%	0.0%	9.59%	9.97%	10.01%	9.97%	10.09%	9.79%	9.89%	9.75%	9.10%	8.86%	8.46%	8.97%	9.26%
Nephropathy	<0.001	5.3%	0.9%	16.30%	18.31%	18.48%	19.28%	19.97%	20.28%	20.47%	21.24%	22.08%	23.36%	24.00%	25.97%	27.43%
Neuropathy	<0.001	3.9%	0.6%	16.52%	16.84%	17.29%	18.27%	18.51%	18.73%	19.25%	20.24%	20.74%	21.97%	23.02%	24.50%	24.85%
Peripheral																
Vascular	0.16	2 10/	0.20/	10 110/	10.170/	10.100/	12 200/	11.060/	11 7 (0/	11.010/	11.000/	11.050/	12 210/	12 100/	14.220/	15.200/
Disease Retinopathy	0.16	2.1%	0.3%	12.11%	12.17%	12.13%	12.38%	11.96%	11.76%	11.91%	11.92%	11.95%	12.21%	13.10%	14.32%	15.39%
Severe	0.003	-3.6%	-0.3%	9.22%	8.53%	7.97%	7.83%	6.93%	6.46%	6.57%	6.70%	6.64%	7.03%	6.33%	4.76%	4.91%
Hyperglycemi																
a	0.26	-0.8%	0.0%	1.00%	1.04%	1.05%	0.93%	0.91%	0.95%	1.01%	0.94%	0.96%	0.94%	0.95%	1.04%	0.89%
Severe																
Hypoglycemi	0.08	-2.6%	-0.1%	4.99%	4.94%	5.01%	4.91%	4.76%	4.50%	4.45%	4.45%	5.18%	5.58%	3.06%	3.19%	3.28%
a Actively	0.08	-2.070	-0.170	4.99%	4.9470	5.0170	4.9170	4./070	4.30%	4.4370	4.4370	3.1070	3.3870	5.0070	5.1970	3.2070
Managed																
CCS Health																
Conditions																
1 CCS	0.21	-1.8%	-0.1%	8.47%	8.71%	8.61%	6.85%	6.23%	5.80%	5.63%	6.05%	7.85%	8.35%	7.78%	6.25%	6.54%
Category 2 CCS	0.21	-1.070	-0.170	0.4/70	0./170	0.0170	0.8370	0.2370	3.80%	3.0370	0.0370	7.8370	0.5570	1./070	0.2370	0.3470
Categories	<0.001	-2.6%	-0.1%	1.90%	1.86%	1.83%	1.64%	1.46%	1.37%	1.31%	1.30%	1.32%	1.27%	1.29%	1.27%	1.25%
3 CCS																
Categories 4 CS	<0.001	-3.0%	-0.1%	3.14%	3.23%	3.13%	2.82%	2.60%	2.45%	2.31%	2.16%	2.19%	1.97%	2.03%	2.01%	1.90%
4 CS Categories	<0.001	-3.1%	-0.2%	5.06%	5.13%	4.99%	4.73%	4.62%	4.59%	4.13%	3.87%	3.72%	3.26%	3.26%	3.10%	2.99%
5 CCS																
Categories	<0.001	-2.5%	-0.1%	5.77%	5.31%	5.20%	5.11%	5.00%	4.92%	4.78%	4.57%	4.51%	4.09%	4.25%	4.10%	3.89%
6 CCS	<0.001	2.50/	0.20/	(170/	5.75%	5 (20/	5.60%	5 500/	5 500/	5 210/	5 100/	5.010/	1.5(0)	4 5 9 9 /	4 410/	4 1 4 0 /
Categories 7 CCS	<0.001	-2.5%	-0.2%	6.17%	3./3%	5.62%	3.00%	5.59%	5.59%	5.31%	5.12%	5.01%	4.56%	4.58%	4.41%	4.14%
Categories	<0.001	-2.0%	-0.1%	6.21%	5.81%	5.82%	5.85%	5.78%	5.77%	5.67%	5.44%	5.30%	4.98%	5.02%	4.86%	4.59%
8 CCS																
Categories	0.003	-1.5%	-0.1%	5.97%	5.71%	5.47%	5.65%	5.69%	5.75%	5.66%	5.50%	5.31%	5.12%	5.13%	5.01%	4.80%
9 CCS Categories	0.011	-1.3%	-0.1%	5.74%	5.36%	5.28%	5.32%	5.43%	5.49%	5.54%	5.40%	5.26%	5.20%	5.13%	5.00%	4.78%
Categories	0.011	-1.J/0	-0.170	J. 77/0	5.5070	5.2070	5.5270	5.7570	5.7770	J.JT/0	5.4070	5.2070	5.2070	5.1570	5.0070	T./0/0

>=10 CCS Categories	<0.001	2.0%	1.0%	51.58%	53.13%	54.05%	56.41%	57.60%	58.28%	59.66%	60.59%	59.54%	61.18%	61.53%	63.99%	65.11%
Mean (SD) CCS Categories	<0.001	1.8%	0.225	12.29 (9.62)	12.81 (10.26)	13.05 (10.41)	13.48 (10.40)	13.68 (10.33)	13.79 (10.31)	14.03 (10.35)	14.19 (10.43)	13.96 (10.53)	14.32 (10.73)	14.37 (10.63)	14.94 (10.73)	15.21 (10.87)
Health Care Utilization																
Mean (SD) Ambulatory visits	0.230	0.2%	0.053	8.01 (6.66)	8.19 (7.02)	8.32 (7.18)	8.65 (7.23)	8.58 (7.06)	8.43 (6.91)	8.40 (6.89)	8.48 (7.05)	7.94 (6.87)	7.87 (6.90)	8.00 (6.90)	8.26 (6.94)	8.17 (6.90)
Mean (SD) Emergency Department Visits	< 0.001	4.7%	0.019	0.41 (1.19)	0.47 (1.26)	0.51 (1.34)	0.53 (1.38)	0.52	0.54	0.54	0.55	0.56 (1.43)	0.57 (1.45)	0.65	0.66	0.66 (1.53)
Mean (SD) Hospitalizatio	0.002	-1.1%	-0.005	0.41 (0.87)	0.43 (0.94)	0.42 (0.93)	0.41 (0.93)	0.40 (0.92)	0.38 (0.91)	0.37 (0.90)	0.36 (0.87)	0.34 (0.84)	0.34 (0.83)	0.34 (0.84)	0.35 (0.85)	0.35 (0.85)
HbA _{1c}																
Mean (SD) HbA _{1c}	0.15	-0.03%	-0.38%	7.05 (1.31)	6.97 (1.26)	6.98 (1.29)	7.10 (1.34)	7.11 (1.34)	7.12 (1.39)	7.10 (1.38)	7.11 (1.38)	7.20 (1.44)	7.15 (1.40)	7.19 (1.44)	7.09 (1.41)	7.00 (1.40)
$HbA_{1c} < 7.0\%$	0.35	0.33%	0.19%	58.2%	62.6%	62.2%	58.6%	57.7%	58.2%	59.1%	58.4%	55.5%	57.1%	56.2%	59.0%	60.7%
$HbA_{1c} \ge 8.0\%$	0.01	0.53%	0.09%	17.4%	14.9%	16.2%	18.1%	18.5%	18.8%	18.6%	19.2%	21.2%	20.0%	21.1%	19.4%	18.6%

Supplemental Table S5. Confidence Intervals for Point Estimates for Commercial Cohort Values represent upper and lower bounds of 95% confidence intervals around point estimates

Year	Total Population	Age		>= 10 CCS Categories		>= 10 med classes		>= 3 CV classes		>= 3 glucose classes		>= 1 lipid classes		>= 1 DCSI		Mean glucose classes	
		Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper
2006	393046	51.90	51.96	33.1%	33.4%	12.5%	12.7%	20.3%	20.5%	11.5%	11.7%	36.9%	37.2%	33.2%	33.5%	1.106	1.114
2007	436460	52.17	52.23	33.5%	33.8%	19.0%	19.2%	26.5%	26.7%	16.3%	16.5%	44.3%	44.6%	32.4%	32.6%	1.296	1.304
2008	451113	52.37	52.43	34.4%	34.6%	23.6%	23.8%	32.0%	32.3%	18.0%	18.2%	51.4%	51.7%	31.9%	32.2%	1.416	1.424
2009	460069	52.68	52.74	35.2%	35.4%	24.7%	25.0%	33.0%	33.3%	18.1%	18.3%	54.3%	54.6%	31.8%	32.1%	1.426	1.434
2010	456654	52.94	53.00	35.3%	35.6%	25.2%	25.5%	33.3%	33.5%	18.1%	18.3%	55.4%	55.7%	31.6%	31.9%	1.416	1.424
2011	459222	53.23	53.29	35.4%	35.7%	25.2%	25.4%	33.1%	33.4%	17.9%	18.1%	55.7%	56.0%	31.2%	31.4%	1.406	1.414
2012	452232	53.43	53.49	36.2%	36.5%	24.5%	24.8%	32.7%	33.0%	17.1%	17.4%	55.1%	55.4%	30.9%	31.2%	1.366	1.374
2013	445045	53.67	53.73	36.7%	37.0%	24.2%	24.4%	32.5%	32.7%	17.1%	17.4%	54.9%	55.2%	31.2%	31.5%	1.366	1.374
2014	400824	53.49	53.55	35.3%	35.6%	23.5%	23.8%	31.2%	31.5%	18.0%	18.2%	54.9%	55.2%	30.5%	30.8%	1.406	1.414
2015	412659	53.57	53.63	37.4%	37.7%	23.6%	23.8%	30.9%	31.2%	18.9%	19.2%	54.3%	54.6%	31.8%	32.1%	1.426	1.434
2016	432683	53.72	53.78	36.9%	37.2%	24.0%	24.2%	31.0%	31.3%	19.7%	20.0%	55.2%	55.5%	31.5%	31.8%	1.466	1.474
2017	440304	53.87	53.93	37.8%	38.1%	24.7%	25.0%	31.3%	31.6%	20.6%	20.8%	56.6%	56.9%	31.6%	31.9%	1.506	1.514
2018	386845	54.45	54.51	38.8%	39.1%	26.7%	27.0%	32.5%	32.8%	22.9%	23.2%	59.2%	59.5%	32.7%	33.0%	1.586	1.594

Year	Mean CV classes		Mean lipid classes		# with lab results	HbA1c < 7		HBA1 c >= 8		Mean ambul atory		Mean inpatie nt		Mean ED	
	Lower	Upper	Lower	Upper		Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper
2006	1.125	1.135	0.488	0.492	85397	48.6%	49.2%	27.7%	28.3%	6.841	6.879	0.189	0.193	0.257	0.263
2007	1.405	1.415	0.608	0.612	76577	53.0%	53.7%	24.8%	25.4%	6.772	6.808	0.179	0.182	0.257	0.263
2008	1.685	1.695	0.698	0.702	110196	52.7%	53.2%	25.8%	26.3%	6.712	6.748	0.170	0.174	0.257	0.263
2009	1.735	1.745	0.718	0.722	125917	49.9%	50.4%	27.1%	27.6%	6.732	6.768	0.165	0.169	0.257	0.263
2010	1.745	1.755	0.718	0.722	126572	49.0%	49.5%	27.6%	28.1%	6.602	6.638	0.159	0.162	0.257	0.263

2011	1.745	1.755	0.708	0.712	119634	50.9%	51.4%	27.1%	27.7%	6.492	6.528	0.152	0.155	0.267	0.273
2012	1.725	1.735	0.678	0.682	115219	50.9%	51.4%	27.0%	27.5%	6.412	6.448	0.143	0.146	0.267	0.273
2013	1.715	1.725	0.658	0.662	135746	49.7%	50.2%	28.5%	29.0%	6.462	6.498	0.136	0.139	0.267	0.273
2014	1.665	1.675	0.648	0.652	124359	47.1%	47.6%	30.1%	30.6%	6.211	6.249	0.125	0.128	0.277	0.283
2015	1.655	1.665	0.628	0.632	134410	46.5%	47.0%	30.2%	30.7%	6.152	6.188	0.124	0.127	0.287	0.293
2016	1.675	1.685	0.628	0.632	151323	46.9%	47.4%	29.9%	30.3%	6.132	6.168	0.122	0.124	0.297	0.303
2017	1.695	1.705	0.638	0.642	155530	48.9%	49.4%	28.7%	29.2%	6.142	6.178	0.119	0.122	0.297	0.303
2018	1.764	1.776	0.668	0.672	127663	50.2%	50.8%	27.5%	28.0%	6.171	6.209	0.111	0.114	0.287	0.293

Supplemental Table S6. Confidence Intervals for Point Estimates for Medicare Advantage Cohort Values represent upper and lower bounds of 95% confidence intervals around point estimates

Year	Total Population	Age		>= 10 CCS Categories		>= 10 med classes		>= 3 CV classes		>= 3 glucose classes		>= 1 lipid classes		>= 1 DCSI		Mean glucose classes	
		Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper
2006	65583	70.06	70.16	51.2%	52.0%	37.3%	38.0%	53.8%	54.6%	16.3%	16.9%	52.3%	53.1%	58.7%	59.5%	1.482	1.498
2007	97816	70.57	70.67	52.8%	53.4%	41.0%	41.6%	53.1%	53.7%	17.1%	17.6%	55.1%	55.8%	59.1%	59.7%	1.433	1.447
2008	133230	70.65	70.73	53.8%	54.3%	40.6%	41.1%	52.5%	53.1%	16.2%	16.6%	57.4%	57.9%	59.0%	59.5%	1.384	1.396
2009	184439	70.56	70.64	56.2%	56.6%	41.9%	42.3%	53.1%	53.5%	16.1%	16.4%	60.7%	61.2%	59.8%	60.2%	1.375	1.385
2010	242461	70.85	70.91	57.4%	57.8%	43.4%	43.8%	53.6%	54.0%	16.2%	16.5%	63.3%	63.7%	60.0%	60.4%	1.375	1.385
2011	291044	71.01	71.07	58.1%	58.5%	44.5%	44.8%	53.7%	54.1%	15.6%	15.8%	65.1%	65.4%	59.8%	60.2%	1.356	1.364
2012	363848	71.26	71.32	59.5%	59.8%	43.5%	43.8%	52.9%	53.2%	15.0%	15.2%	65.8%	66.1%	60.2%	60.5%	1.336	1.344
2013	410773	71.48	71.54	60.4%	60.7%	43.8%	44.1%	53.0%	53.3%	14.9%	15.1%	66.6%	66.9%	60.5%	60.8%	1.317	1.323
2014	431868	71.79	71.85	59.4%	59.7%	43.7%	44.0%	52.2%	52.5%	15.5%	15.7%	67.4%	67.7%	59.9%	60.2%	1.337	1.343
2015	465814	72.17	72.23	61.0%	61.3%	42.4%	42.7%	51.2%	51.5%	15.3%	15.5%	67.7%	68.0%	60.9%	61.1%	1.317	1.323
2016	656531	71.65	71.69	61.4%	61.6%	44.3%	44.5%	52.1%	52.4%	16.5%	16.7%	69.0%	69.3%	61.6%	61.8%	1.377	1.383
2017	819285	71.88	71.92	63.9%	64.1%	45.8%	46.1%	52.2%	52.4%	17.1%	17.2%	70.4%	70.6%	63.7%	63.9%	1.387	1.393
2018	797151	72.62	72.66	65.0%	65.2%	48.4%	48.6%	53.8%	54.0%	18.0%	18.2%	73.1%	73.3%	65.0%	65.2%	1.417	1.423
C	ean V Isses	Mean lipid classe		# with lab results	HbA1c < 7		HBA1 c >= 8		Mean ambul atory		Mean inpatio nt	,	Mear ED	1			
Lo	ower Upper	· Lower	· Upper		Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper	Lowe	r Uppe	r		
,	2.695 2.72	0.63	5 0.64	5 11174	57.3%	59.1%	16.7%	18.1%	7.959	8.061	0.40	0.41	4 0.4	0.4	19		
,	2.687 2.71	.3 0.69	5 0.70	5 13886	61.8%	63.4%	14.3%	15.5%	8.146	5 8.234	0.424	4 0.43	6 0.4	62 0.4	78		
	2.669 2.69	0.71	6 0.72	4 23010	61.5%	62.8%	15.7%	16.7%	8.281	8.359	0.410	5 0.42	6 0.5	03 0.5	17		
	2.711 2.72	.9 0.73	7 0.74	3 35007	58.0%	59.1%	17.7%	18.5%	8.617	8.683	0.400	5 0.41	4 0.52	24 0.5	36		
	2.742 2.75	0.76	0.77	3 44782	57.3%	58.2%	18.1%	18.8%	8.552	2 8.608	0.39	0.39	9 0.5	15 0.5	25		
	2.743 2.75	0.77	8 0.78	2 48910	57.7%	58.6%	18.4%	19.1%	8.405	5 8.455	0.380	0.38	7 0.5	35 0.5	45		

2.714	2.726	0.778	0.782	72013	58.7%	59.4%	18.3%	18.9%	8.378	8.422	0.371	0.376	0.535	0.545
2.724	2.736	0.778	0.782	116709	58.2%	58.7%	19.0%	19.4%	8.458	8.502	0.357	0.363	0.546	0.554
2.694	2.706	0.778	0.782	121450	55.3%	55.8%	21.0%	21.4%	7.920	7.960	0.339	0.344	0.556	0.564
2.644	2.656	0.768	0.772	144427	56.8%	57.3%	19.8%	20.2%	7.850	7.890	0.333	0.338	0.566	0.574
2.695	2.705	0.779	0.781	205118	55.9%	56.4%	20.9%	21.2%	7.983	8.017	0.338	0.342	0.646	0.654
2.706	2.714	0.799	0.801	276675	58.9%	59.2%	19.3%	19.6%	8.245	8.275	0.344	0.348	0.657	0.663
2.786	2.794	0.829	0.831	261998	60.5%	60.9%	18.4%	18.7%	8.155	8.185	0.344	0.347	0.657	0.663